Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudolf Prager

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Metabolism: Clinical and Experimental|July 19, 2003
Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patientsBernhard Ludvik, Werner Waldhäusl, Rudolf Prager, et al.
Diabetes Technology & Therapeutics|March 6, 2004
Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoringHeidemarie Abrahamian, Mario Francesconi, Anita Loiskandl, et al.
Wiener Klinische Wochenschrift|June 2, 2005
[The metabolic syndrome: effects of a pronounced weight loss induced by bariatric surgery]Julia Engl, Ursula Hanusch-Enserer, Rudolf Prager, et al.
Wiener Klinische Wochenschrift|January 11, 2015
Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE studyHelmut Brath, Christoph Bialek, Ewald Gingl, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 3, 2003
Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disordersAndrea Tura, Giovanni Pacini, Alexandra Kautzky-Willer, et al.
Diabetes, Obesity & Metabolism|December 6, 2017
Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review studyHermione Price, Matthias Blüher, Rudolf Prager, et al.
Wiener Klinische Wochenschrift|June 16, 2007
Relation of fasting plasma peptide YY to glucose metabolism and cardiovascular risk factors after restrictive bariatric surgeryUrsula Hanusch-Enserer, Mohammed A Ghatei, Edmund Cauza, et al.
Diabetes, Obesity & Metabolism|January 27, 2017
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trialStewart B Harris, Győző Kocsis, Rudolf Prager, et al.
Diabetes Care|October 29, 2002
Influence of metabolic control on splanchnic glucose uptake, insulin sensitivity, and the time required for glucose absorption in patients with type 1 diabetesPetra Georg, Alexandra Kautzky-Willer, Katja Mahdjoobian, et al.
Diabetes Care|January 5, 2002
The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized studyBernhard H Ludvik, Katja Mahdjoobian, Werner Waldhaeusl, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Metabolism: Clinical and Experimental|July 19, 2003
Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patientsBernhard Ludvik, Werner Waldhäusl, Rudolf Prager, et al.
Diabetes Technology & Therapeutics|March 6, 2004
Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoringHeidemarie Abrahamian, Mario Francesconi, Anita Loiskandl, et al.
Wiener Klinische Wochenschrift|June 2, 2005
[The metabolic syndrome: effects of a pronounced weight loss induced by bariatric surgery]Julia Engl, Ursula Hanusch-Enserer, Rudolf Prager, et al.
Wiener Klinische Wochenschrift|January 11, 2015
Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE studyHelmut Brath, Christoph Bialek, Ewald Gingl, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 3, 2003
Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disordersAndrea Tura, Giovanni Pacini, Alexandra Kautzky-Willer, et al.
Diabetes, Obesity & Metabolism|December 6, 2017
Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review studyHermione Price, Matthias Blüher, Rudolf Prager, et al.
Wiener Klinische Wochenschrift|June 16, 2007
Relation of fasting plasma peptide YY to glucose metabolism and cardiovascular risk factors after restrictive bariatric surgeryUrsula Hanusch-Enserer, Mohammed A Ghatei, Edmund Cauza, et al.
Diabetes, Obesity & Metabolism|January 27, 2017
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trialStewart B Harris, Győző Kocsis, Rudolf Prager, et al.
Diabetes Care|October 29, 2002
Influence of metabolic control on splanchnic glucose uptake, insulin sensitivity, and the time required for glucose absorption in patients with type 1 diabetesPetra Georg, Alexandra Kautzky-Willer, Katja Mahdjoobian, et al.
Diabetes Care|January 5, 2002
The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized studyBernhard H Ludvik, Katja Mahdjoobian, Werner Waldhaeusl, et al.
Pageof 7